95 related articles for article (PubMed ID: 29273262)
1. Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial.
Hechtner M; Krause M; König J; Appold S; Hornemann B; Singer S; Baumann M
Radiother Oncol; 2018 Feb; 126(2):283-290. PubMed ID: 29273262
[TBL] [Abstract][Full Text] [Related]
2. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D;
Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247
[TBL] [Abstract][Full Text] [Related]
3. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
[TBL] [Abstract][Full Text] [Related]
4. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
[TBL] [Abstract][Full Text] [Related]
5. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial.
Soliman M; Yaromina A; Appold S; Zips D; Reiffenstuhl C; Schreiber A; Thames HD; Krause M; Baumann M
Radiother Oncol; 2013 Mar; 106(3):299-304. PubMed ID: 23333018
[TBL] [Abstract][Full Text] [Related]
6. Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy.
Bütof R; Löck S; Soliman M; Haase R; Perrin R; Richter C; Appold S; Krause M; Baumann M
Radiother Oncol; 2020 Feb; 143():44-50. PubMed ID: 31767470
[TBL] [Abstract][Full Text] [Related]
7. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome.
Bentzen SM; Saunders MI; Dische S
Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):372-81. PubMed ID: 12555876
[TBL] [Abstract][Full Text] [Related]
8. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer.
Langendijk JA; Aaronson NK; de Jong JM; ten Velde GP; Muller MJ; Lamers RJ; Slotman BJ; Wouters EF
J Clin Oncol; 2001 Apr; 19(8):2123-33. PubMed ID: 11304764
[TBL] [Abstract][Full Text] [Related]
9. Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy.
Ozturk A; Sarihan S; Ercan I; Karadag M
Am J Clin Oncol; 2009 Feb; 32(1):65-72. PubMed ID: 19194128
[TBL] [Abstract][Full Text] [Related]
10. Quality of life after curative radiotherapy in Stage I non-small-cell lung cancer.
Langendijk JA; Aaronson NK; de Jong JM; ten Velde GP; Muller MJ; Slotman BJ; Wouters EF
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):847-53. PubMed ID: 12095549
[TBL] [Abstract][Full Text] [Related]
11. Quality of life during 5 years after stereotactic radiotherapy in stage I non-small cell lung cancer.
Ubels RJ; Mokhles S; Andrinopoulou ER; Braat C; van der Voort van Zyp NC; Aluwini S; Aerts JG; Nuyttens JJ
Radiat Oncol; 2015 Apr; 10():98. PubMed ID: 25896787
[TBL] [Abstract][Full Text] [Related]
12. High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL.
Pijls-Johannesma M; Houben R; Boersma L; Grutters J; Seghers K; Lambin P; Wanders R; De Ruysscher D
Radiother Oncol; 2009 Jun; 91(3):443-8. PubMed ID: 19297049
[TBL] [Abstract][Full Text] [Related]
13. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
[TBL] [Abstract][Full Text] [Related]
14. [CHARTWEL-Bronchus (ARO 97-1): a randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-call bronchial carcinoma].
Baumann M; Herrmann T; Matthiessen W; Koch R; Strelocke K; Paul U
Strahlenther Onkol; 1997 Dec; 173(12):663-7. PubMed ID: 9454350
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two dimensional and three dimensional radiotherapy treatment planning in locally advanced non-small cell lung cancer treated with continuous hyperfractionated accelerated radiotherapy weekend less.
Wilson EM; Joy Williams F; Lyn BE; Aird EG
Radiother Oncol; 2005 Mar; 74(3):307-14. PubMed ID: 15763312
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer.
Zhang W; Liu Q; Dong X; Lei P
J Thorac Dis; 2015 Mar; 7(3):478-85. PubMed ID: 25922728
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
18. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study.
Langendijk JA; ten Velde GP; Aaronson NK; de Jong JM; Muller MJ; Wouters EF
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):149-55. PubMed ID: 10758317
[TBL] [Abstract][Full Text] [Related]
19. Long-term quality of life in early-stage non-small cell lung cancer patients treated with robotic stereotactic ablative radiation therapy.
Mathieu D; Campeau MP; Bahig H; Larrivée S; Vu T; Lambert L; Lavoie C; Roberge D; Doucet R; Carrier JF; Gorgos A; Fortin B; Filion E
Pract Radiat Oncol; 2015; 5(4):e365-73. PubMed ID: 25680997
[TBL] [Abstract][Full Text] [Related]
20. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
